These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 22130166)

  • 1. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
    Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
    J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
    Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
    Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
    Wistuba-Hamprecht K; Martens A; Heubach F; Romano E; Geukes Foppen M; Yuan J; Postow M; Wong P; Mallardo D; Schilling B; Di Giacomo AM; Khammari A; Dreno B; Maio M; Schadendorf D; Ascierto PA; Wolchok JD; Blank CU; Garbe C; Pawelec G; Weide B
    Eur J Cancer; 2017 Mar; 73():61-70. PubMed ID: 28167454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
    Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
    Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
    Di Giacomo AM; Calabrò L; Danielli R; Fonsatti E; Bertocci E; Pesce I; Fazio C; Cutaia O; Giannarelli D; Miracco C; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2013 Jun; 62(6):1021-8. PubMed ID: 23591982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
    Yuan J; Adamow M; Ginsberg BA; Rasalan TS; Ritter E; Gallardo HF; Xu Y; Pogoriler E; Terzulli SL; Kuk D; Panageas KS; Ritter G; Sznol M; Halaban R; Jungbluth AA; Allison JP; Old LJ; Wolchok JD; Gnjatic S
    Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16723-8. PubMed ID: 21933959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
    Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
    Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
    Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
    Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
    Weber JS; Kudchadkar RR; Yu B; Gallenstein D; Horak CE; Inzunza HD; Zhao X; Martinez AJ; Wang W; Gibney G; Kroeger J; Eysmans C; Sarnaik AA; Chen YA
    J Clin Oncol; 2013 Dec; 31(34):4311-8. PubMed ID: 24145345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
    de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
    Oncotarget; 2017 Mar; 8(13):21539-21553. PubMed ID: 28423487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
    Tarhini AA; Edington H; Butterfield LH; Lin Y; Shuai Y; Tawbi H; Sander C; Yin Y; Holtzman M; Johnson J; Rao UN; Kirkwood JM
    PLoS One; 2014; 9(2):e87705. PubMed ID: 24498358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
    Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
    Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
    J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.
    Zelba H; Weide B; Martens A; Derhovanessian E; Bailur JK; Kyzirakos C; Pflugfelder A; Eigentler TK; Di Giacomo AM; Maio M; Aarntzen EH; de Vries J; Sucker A; Schadendorf D; Büttner P; Garbe C; Pawelec G
    Clin Cancer Res; 2014 Aug; 20(16):4390-9. PubMed ID: 24938524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
    Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
    Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
    Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.